

20 ANIVERSARIO DE LA REVISTA INTERNACIONAL DE MEDICINA Y CIENCIAS DE LA ACTIVIDAD FÍSICA Y EL DEPORTE

Jornada de celebración y reflexión: ¿Publicar en una Revista incluida en JCR? Visión de editores, evaluadores y autores

Universidad Autónoma de Madrid, 20 de noviembre de 2020

Quien y cómo en la ética de las publicaciones científicas

Remedios Melero. IATA-CSIC, Valencia, España



Temas tratados

1. Partes implicadas y relacionadas con la publicación científica (revistas) y su papel en la integridad en la investigación
2. Declaraciones y códigos éticos sobre integridad en la investigación
3. Malas prácticas y sus consecuencias
4. Casos de malas prácticas y recomendaciones

Sectores implicados en las publicaciones (revistas científicas) en función de sus lecturas éticas



Declaraciones y códigos éticos

Declaración de Singapur sobre la Integridad en la Investigación. 2nd World Conference on Research Integrity, 2010. <https://wcrif.org/statement>

1.

6. Autoría. Los investigadores deberían asumir la responsabilidad por sus contribuciones a todas las publicaciones, solicitudes de financiamiento, informes y otras formas de presentar su investigación. *En las listas de autores deben figurar todos aquellos que cumplan con los criterios aplicables de autoría y sólo ellos.*

7. Reconocimientos en las publicaciones. Los investigadores deberían mencionar en las publicaciones los nombres y funciones de aquellas personas que hubieran hecho aportes significativos a la investigación, incluyendo redactores, patrocinadores y otros que no cumplan con los criterios de autoría.

8. Revisión por pares. Al evaluar el trabajo de otros, los investigadores deberían brindar evaluaciones imparciales, rápidas y rigurosas y respetar la confidencialidad.

9. Conflictos de intereses. Los investigadores deberían revelar cualquier conflicto de intereses, ya sea económico o de otra índole, que comprometiera la confiabilidad de su trabajo, en propuestas de investigación, publicaciones y comunicaciones públicas, así como en cualquier actividad de evaluación.

...14.

Ley 14/2011, de 1 de junio, de la Ciencia, la Tecnología y la Innovación

Artículo 10. *Comité Español de Ética de la Investigación.*

1. Se crea el Comité Español de Ética de la Investigación, adscrito al Consejo de Política Científica, Tecnológica y de Innovación, como órgano colegiado, independiente y de carácter consultivo, sobre materias relacionadas con la ética profesional en la investigación científica y técnica.

2. Son funciones del Comité Español de Ética de la Investigación:

- a) **Emitir informes, propuestas y recomendaciones** sobre materias relacionadas con la ética profesional en la investigación científica y técnica.
- b) Establecer los **principios generales para la elaboración de códigos de buenas prácticas** de la investigación científica y técnica, que incluirán la resolución de conflictos de intereses entre las actividades públicas y privadas. Estos códigos serán desarrollados por los Comités de Ética de la Investigación y por el Comité de Bioética de España.
- c) **Representar a España** en foros y organismos supranacionales e internacionales relacionados con la ética de la investigación, salvo en materia de bioética en la que la representación de España corresponderá al Comité de Bioética de España.
- d) **Impulsar la creación de comisiones de ética** vinculadas a los agentes ejecutores del Sistema Español de Ciencia, Tecnología e Innovación.
- e) Elaborar una **memoria anual de actividades**.
- f) Cualesquiera otras que le encomiende el Consejo de Política Científica, Tecnológica y de Innovación o la normativa de desarrollo de esta ley.

Comités- Consejos

Comité español de ética de la investigación

Previsto en la ley de la Ciencia cuya composición (12 expertos) se pactó con las CCAA-ministro Pedro Luque (nov 2018)

Comités de ética por instituciones (establecen sus reglas basadas en la normativa vigente) para **dar respuesta** a las necesidades actuales o que en el futuro se planteen respecto de la investigación científica relacionada con la protección de los derechos fundamentales de las personas, el bienestar de los animales y el medio ambiente, y al respeto de los principios y compromisos bioéticos asumidos por la Comunidad científica y los Estatutos propios de la Institución.

Códigos de conducta. Conjunto de deberes y principios éticos por los que se rigen de empresas, asociaciones, instituciones públicas...

Integridad científica y buenas prácticas

La integridad científica comporta la observancia y promoción de principios éticos y responsabilidades profesionales en el ejercicio de la investigación, los cuales inspiran y garantizan la buena praxis.

Inicio » El CSIC » Ética e integridad científica en el CSIC
» Integridad científica y buenas prácticas



Aunque cada vez son más los países en los que existen oficinas, agencias u otras estructuras a nivel nacional dedicadas a integridad científica, existen redes y foros de carácter nacional y transnacional, y se celebran conferencias mundiales sobre el tema, no existe una definición globalmente consensuada de integridad científica.

La integridad científica se corresponde con un patrón de conducta en investigación caracterizado por la observancia y promoción de principios



<https://www.csic.es/es/el-csic/etica/Integridad-cientifica-y-buenas-practicas>

Año 2011



https://www.csic.es/sites/default/files/declaracion_nacional_sobre_integridad_cientifica_castellano-ingles.pdf

Declaración Nacional sobre Integridad Científica Año 2015

La Declaración Nacional está basada en los siguientes aspectos

1. Propósito y objeto de la investigación
2. Fiabilidad de los resultados de investigación
3. Metodología
4. Registro de datos y resultados
- 5. Difusión y comunicación de resultados**
- 6. Autoría**
7. Gestión de recursos
8. Cooperación en el grupo de investigación
9. Ejercicio del liderazgo
10. Promoción de investigación responsable
11. Colaboración con otras entidades
12. Transferencia de conocimiento
- 13. Evaluación**
- 14. Conflicto de intereses**
15. Política de integridad

Basados en los principios de

- Transparencia
- Difusión
- Cooperación
- Responsabilidad
- Integridad

Código Europeo de Conducta para la Integridad en la Investigación (ALLEA, 2018)

Conducta indebida (*misconduct*) o malas prácticas

- **Invención** se refiere a inventar resultados y registrarlos como si fueran reales.
- **Falsificación** se refiere a manipular materiales, equipos o procesos de la investigación o a cambiar, omitir o suprimir datos o resultados sin justificación.
- **Plagio** se refiere a utilizar el trabajo y las ideas de otras personas sin citar adecuadamente la fuente original, violando así los derechos del autor o autores originales respecto a su producción intelectual.

Incumplimiento de la integridad en la investigación

- **Manipular la autoría** o denigrar el papel de otros investigadores en las publicaciones.
- **Volver a publicar** partes sustanciales de publicaciones propias anteriores, incluidas las traducciones, sin reconocer o citar debidamente el original («autoplagio»)
- **Citar de forma selectiva** para mejorar los propios resultados o para complacer a los editores, los revisores o los colegas
- **Retener resultados** de la investigación
- Permitir que los patrocinadores pongan en peligro la independencia en el proceso de investigación o en la presentación de resultados con el fin de **introducir sesgos**
- Ampliar de manera **innecesaria la bibliografía** de un estudio

Continuación...

- **Acusar** a un investigador de conducta indebida u otras infracciones **de forma maliciosa**
- **Tergiversar** los logros de la investigación
- **Exagerar la importancia** y la relevancia práctica de los resultados
- **Retrasar u obstaculizar** inadecuadamente el trabajo de otros investigadores
- Emplear la experiencia profesional propia para **alentar a que se incumpla la integridad de la investigación**
- **Ignorar supuestos incumplimientos** de la integridad de la investigación cometidos por terceros o encubrir reacciones inadecuadas a conductas indebidas u otro tipo de incumplimientos por parte de las instituciones
- Establecer publicaciones o brindar apoyo **a publicaciones que no cumplen** el proceso de control de calidad de la investigación («publicaciones abusivas»).

El *International Committee of Medical Journals Editors (ICMJE)* recomienda basar la definición de autor en cuatro criterios:

1. Que exista una contribución sustancial a la concepción o diseño del artículo o a la adquisición, análisis o interpretación de los datos
2. Que se haya participado en el diseño del trabajo de investigación o en la revisión crítica de su contenido intelectual
3. Que se haya intervenido en la aprobación de la versión final que vaya a ser publicada
4. Que se tenga capacidad de responder de todos los aspectos del artículo de cara a asegurar que las cuestiones relacionadas con la exactitud o integridad de cualquier parte del trabajo están adecuadamente investigadas y resueltas

Toda persona designada como autor debe cumplir los cuatro criterios que definen la autoría y quien cumpla los cuatro criterios debe ser identificado como autor. Quienes no los cumplan deben ser reconocidos en los agradecimientos

2019

THE HONG KONG PRINCIPLES FOR ASSESSING RESEARCHERS








FOSTERING RESEARCH INTEGRITY



What are the HKP?

The Hong Kong Principles (HKP) were developed as part of the 6th World Conference on Research Integrity. They were developed to reinforce the need to ensure that researchers are rewarded for specific behaviors that promote trustworthy research. The HKP have been developed with the idea that implementation of them could assist in how researchers are assessed for career advancement with a view to strengthen research integrity.

PRINCIPLE	IMPLEMENTATION EXAMPLES
1 Assess responsible research practices.	 The NIH recommends Experimental Design Assistant (EDA) developed by N3CRs. This 10-module on-line tool helps researchers prepare the design and analysis requested for grant applications.
2 Value complete reporting.	 Wellcome Trust's Open Research (WOR) editorial policies require authors to use reporting guidelines for protocols (e.g., SPIRIT) and completed studies (e.g., ARRIVE). The Universidade Federal de Ciências da Saúde de Porto Alegre (UFCSA, Brazil), has a formal course on reporting guidelines that students can complete as formal credit towards their degree.
3 Reward the practice of open science.	 The University of Cambridge has introduced 'data champions'. Delft University of Technology, The Netherlands, is implementing this as a career assessment criterion. The Nanyang Technological University (NTU), Singapore, implemented an Open Access policy in 2011. At NTU's faculty of medicine, random audits are conducted to ensure adherence.
4 Acknowledge a broad range of research activities.	 The Netherlands Organization for Scientific Research is in its third call for replication studies. PLOS Biology and eLife have meta-research sections in their respective journals.
5 Recognize essential other tasks such as peer reviewing and mentoring.	 The University of Glasgow's academic promotion criteria rewards researchers for participation in peer review and other related activities (e.g., journal editorship).

The full HKP article can be accessed at <https://osf.io/m9abx>. Individuals and/or academic institutions and other groups can endorse the HKP at <https://www.wcrif.org/guidance/hong-kong-principles>

1. Valorar las prácticas de investigación responsables
2. Valorar seguir protocolos estandarizados para determinados informes
3. Recompensar la práctica de la ciencia abierta
4. Reconocer una amplia gama de actividades de investigación
5. **Reconocer otras tareas esenciales como la revisión por pares y actividades relacionadas (p.e. ser editor)**

Malas prácticas y sus consecuencias

Autores/investigadores

- La Investigación que infringe códigos o protocolos (p.e. cuando se trabaja con personas o animales)
- Fabricación de datos o resultados
- Falsificación de datos , incluida la manipulación de imágenes
- Plagio
- Información selectiva (p.e. ocultación de datos desfavorables, p-hacking)
- Publicación redundante (*salami publication*)
- Autoría inapropiada
- Autoría “honorífica” y autores “fantasmas”
- Conflictos de intereses no declarados



Editores

- Sesgo en la selección de originales
- Sesgo en la elección de revisores
- Trato preferente a amigos o colegas
- Brecha en la confidencialidad
- Retraso intencionado

Recensores/entidad editora:

- Plagio (de ideas, texto o de datos)
- Conflicto de intereses no declarado
- Brecha en la confidencialidad
- Retraso intencionado



Entidad financiadora/patrocinadora

- Eliminación de resultados que no convienen
- Retraso de las publicaciones
- No facilitar a los autores el acceso a los datos
- Intento de manipular la representación de los descubrimientos
- No revelar cual es su implicación en la investigación

Consecuencia de las malas o fraudulentas prácticas:

- Desconfianza den las publicaciones y en la investigación
- Daños en las carreras profesionales y de la instituciones
- Pérdida de tiempo y esfuerzo
- Posible desviación de fondos a determinados sectores

Casos de malas prácticas



y recomendaciones




Además, de cómo se expresan los datos, la calidad y estandarización de los datos importa para facilitar una información que beneficie a toda la sociedad. El acceso a los datos es relevante para el avance de las investigaciones

Importa de los datos

- Repetibilidad
- Reproducibilidad
- Accesibilidad
- Facilidad
- Calidad


<https://theconversation.com/covid-19-la-malinterpretacion-de-los-datos-de-la-pandemia-dana-la-confianza-del-publico-149387>

Khelfaoui, M. et Gingras, Y. (2020). Branding Scholarly Journals: Transmuting Symbolic Capital into Economic Capital. Montréal : Centre interuniversitaire de recherche sur la science et la technologie.



If your manuscript is not accepted...

- (don't) appeal
- transfer to...



Journal Title	Launched in	Subject Category	2019 JCR Rank
<i>Nature Plants</i>	2015	Plant science	3
<i>Nature Energy</i>	2016	Energy and fuels	1
<i>Nature Microbiology</i>	2016	Microbiology	4
<i>Nature Astronomy</i>	2017	Astronomy and astrophysics	4
<i>Nature Biomed. Engineering</i>	2017	Biomedical engineering	1
<i>Nature Ecology & Evolution</i>	2017	Evolutionary biology	3
<i>Nature Human Behaviour</i>	2017	Neurosciences	11
<i>Nature Catalysis</i>	2018	Physical chemistry	2
<i>Nature Electronics</i>	2018	Engineering, electrical & electronic	1
<i>Nature Sustainability</i>	2018	Environmental studies	1
<i>Lancet Gastro. & Hepatol.</i>	2016	Gastroenterology & hepatology	5
<i>Lancet Public Health</i>	2016	Public, environmental health	2
<i>Lancet Child & Adolesc. Health</i>	2017	Pediatrics	2
<i>Science Advances</i>	2015	Multidisciplinary	4
<i>Science Robotics</i>	2016	Robotics	1
<i>Science Immunology</i>	2016	Immunology	7
<i>Cell Systems</i>	2015	Cell biology	27
<i>ACS Central Science</i>	2015	Multidisciplinary	16
<i>ACS Infectious Diseases</i>	2015	Infectious diseases	16
<i>ACS Energy Letters</i>	2016	Energy and fuels	6
<i>ACS Sensors</i>	2016	Nanoscience & nanotechnology	24
<i>ACS Earth and Space Chem.</i>	2017	Geochemistry and geophysics	21
<i>ACS Applied Bio Materials</i>	2018	Biomedical engineering	43
<i>ACS Applied Energy Mater.</i>	2018	Energy and fuels	39

Surgisphere: governments and WHO changed Covid-19 policy based on suspect data from tiny US company

Surgisphere, whose employees appear to include a sci-fi writer and adult content model, provided database behind Lancet and New England Journal of Medicine hydroxychloroquine studies



<https://www.theguardian.com/world/2020/jun/03/covid-19-surgisphere-who-world-health-organization-hydroxychloroquine>

Comment

Expression of concern: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

The Lancet Editors

^a The Lancet, London EC2Y 5AS, UK

Available online 3 June 2020.



Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis

Published Online
June 4, 2020
[https://doi.org/10.1016/S0140-6736\(20\)31324-6](https://doi.org/10.1016/S0140-6736(20)31324-6)

After publication of our Lancet Article,^a several concerns were raised with respect to the veracity of the data and analyses conducted by Surgisphere Corporation and its founder and our co-author, Sapan Desai, in our publication. We launched an independent third-party peer review of Surgisphere with the consent of Sapan Desai to evaluate the origination of the database elements, to confirm the completeness of the database, and to replicate the analyses presented in the paper.

Our independent peer reviewers informed us that Surgisphere would not transfer the full dataset, client contracts, and the full ISO audit report to their servers for analysis as such transfer would violate client agreements and confidentiality requirements. As such, our reviewers were not able to conduct an independent and private peer review and therefore notified us of their withdrawal from the peer-review process.

We all entered this collaboration to contribute in good faith and at a time of great need during the COVID-19 pandemic. We deeply apologise to you, the editors, and the journal readership for any embarrassment or inconvenience that this may have caused.

MRM reports personal fees from Abbott, Medtronic, Janssen, Roivant, Triple Gene, Mesoblast, Baim Institute for Clinical Research, Portola, Bayer, NupulseCV, FineHeart, and Leviticus. FR has been paid for time spent as a committee member for clinical trials, advisory boards, other forms of consulting, and lectures or presentations; these payments were made directly to the University of Zurich and no personal payments were received in relation to these trials or other activities since 2018. Before 2018 FR reports grants and personal fees from SJM/Abbott, grants and personal fees from Servier, personal fees from Zoll, personal fees from Astra Zeneca, personal fees from Sanofi, grants and personal fees from Novartis, personal fees from Amgen, personal fees from BMS, personal fees from Pfizer, personal fees from Fresenius, personal fees from Vifor, personal fees from Roche, grants and personal fees from Bayer, personal fees from Cardiorientis, personal fees from Boehringer Ingelheim, other from Heartware, and grants from Mars. ANP declares no competing interests.

^aMandeep R Mehra, Sapan S Desai, Timothy D Henry, M.D., and Amit N. Patel

Editor's Note: This article was published on May 1, 2020, at NEJM.org.

This article has been retracted.

ORIGINAL ARTICLE

Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19

Mandeep R. Mehra, M.D., Sapan S. Desai, M.D., Ph.D., SreyRam Kuy, M.D., M.H.S., Timothy D. Henry, M.D., and Amit N. Patel, M.D.

Article Figures/Media

Metrics

June 18, 2020
N Engl J Med 2020; 382:e102
DOI: 10.1056/NEJMoa2007621

22 References 229 Citing Articles

Abstract

Related Articles

Editor's Note: This letter was published on June 4, 2020, at NEJM.org.

CORRESPONDENCE RETRACTION

Retraction: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2007621.

146 Citing Articles

TO THE EDITOR:

Because all the authors were not granted access to the raw data and the raw data could not be made available to a third-party auditor, we are unable to validate the primary data sources underlying our article, "Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19."¹ We therefore request that the article be retracted. We apologize to the editors and to readers of the Journal for the difficulties that this has caused.

<http://retractiondatabase.org/RetractionSearch.aspx> (24399 registros a 10 noviembre 2020)

Version: 1.0.6.0
ISSN 2692-465X

The Retraction Watch Database
Please see this [user guide](#) before you get started

Author(s): Country(s):

Title:

Reason(s) for Retraction:

Subject(s): Article Type(s):

Journal:

Publisher:

Affiliation(s):

Notes:


URL:

[Clear Search](#) [Search](#)

Your search returned a large number of results. Only 600 are displayed. Narrow your search to view all results.

Retraction or Other Notices Title/Subject(s)/Journal — Publisher/Affiliation(s)/Retraction Watch Post URL(s) 600 Items Displayed Out of 24399 Item(s) Found	Reason(s)	Author(s)	Original Paper Date/PubMedID/DOI	Retraction or Other Notices Date/PubMedID/DOI	Article Type(s) Nature of Notice	Countries Paywalled? Notes
paradox in melanoma: more patients fewer publications (HSC) Medicine - Dermatology; (HSC) Medicine - Oncology; (HSC) Public Health and Safety; <i>Melanoma Research — Wolters Kluwer - Lippincott Williams & Wilkins</i> Department of Medical Oncology, Institute of Oncology, Istanbul University Department of Medical Oncology, Koc University, Istanbul, Turkey	+Error by Journal/Publisher	Faruk Tas Kayhan Erturk	06/23/2020 32590415 10.1097/CMR.0000000000000684	11/08/2020 33156207 10.1097/CMR.0000000000000698	Research Article Retraction	Turkey No
new-curvature cellular automata model of austenite grain growth (PHY) Materials Science; (PHY) Physics; <i>Materials Research Express — IOP Publishing</i> School of Materials Science and Engineering, Beijing Institute of Technology, Beijing, 100081, People's Republic of China Advanced Research Institute of Multidisciplinary Science, Beijing Institute of Technology, Beijing, 100081, People's Republic of China	+Concerns/Issues About Data +Lack of Approval from Company/Institution	Zhiqiang Li Junsheng Wang Houbing Huang	07/26/2019 00000000 10.1088/2053-1591/ab132c	11/06/2020 00000000 10.1088/2053-1591/abbb86	Research Article Retraction	China No
lockade of tumor growth due to matrix metalloproteinase-9 inhibition is mediated by sequential activation of -integrin, ERK, and NF-κB (BLS) Biochemistry; (BLS) Biology - Cancer; (BLS) Biology - Cellular;	+Concerns/Issues About Data +Manipulation of Images	Praveen Bhoopathi Chandramu Chetty Sateesh Kunal	11/08/2007 17991734 10.1074/jbc.M707931200	11/06/2020 33158922 10.1074/jbc.W120.016338	Research Article Retraction	United States No

Causa de la retractación (20% del total)



The Retraction Watch Leaderboard

Who has the most retractions? Here's our unofficial list (see notes on methodology), which we'll update as more information comes to light:

1. Yoshitaka Fujii (total retractions: 183) See also: [Final report of investigating committee](#), [our reporting](#), [additional coverage](#)
2. Joachim Boldt (129) See also: [Editors-in-chief statement](#), [our coverage](#)
3. Yoshihiro Sato (96) See also: [our coverage](#)
4. Jun Iwamoto (74) See also: [our coverage](#)
5. Diederik Stapel (58) See also: [our coverage](#)
6. Yuhji Saitoh (53) See also: [our coverage](#)
7. Ali Nazari (52) See also: [our coverage](#)
8. Adrian Maxim (48) See also: [our coverage](#)
9. Chen-Yuan (Peter) Chen (43) See also: [SAGE](#), [our coverage](#)
10. Fazlul Sarkar (41) See also: [our coverage](#)
11. Hua Zhong (41) See also: [journal notice](#)

Author(s): Country(s):

Title:

Reason(s) for Retraction:

Subject(s): Article Type(s):

Journal:

Publisher:

Affiliation(s):

Notes:

URL:

[Clear Search](#)

Search

Retraction or Other Notices		Reason(s)	Author(s)	Orig Date/Pu
Title/Subject(s)/Journal — Publisher/Affiliation(s)/Retraction Watch Post URL(s)				
107 Item(s) Found				
travascular Volume Replacement Therapy with Synthetic Colloids: Is There an Influence on Renal Function (HSC) Medicine - Anesthesia/Anaesthesia; (HSC) Medicine - Pharmacology; (HSC) Medicine - Urology/Nephrology; <i>Anesthesia & Analgesia</i> — <i>Wolters Kluwer - Lippincott Williams & Wilkins</i>		+Cites Retracted Work	Joachim Boldt Hans Joachim Priebe	02/01/2003 12538180 10.1213/00000539-2003020100000539-20

Intravascular Volume Replacement Therapy with Synthetic Colloids: Is There an Influence on Renal Function?: Retraction

The article, "Intravascular Volume Replacement Therapy with Synthetic Colloids: Is There an Influence on Renal Function?,"¹ that appeared in the February 2003 issue on pages 376–382, cited multiple articles written by Joachim Boldt that have been retracted due to fraud.

The article is therefore retracted.

Reference

1. Boldt J, Priebe H-J. Intravascular volume replacement therapy with synthetic colloids: is there an influence on renal function? *Anesth Analg*. 2003;96:376–382.

Retractación por citar artículos retractados

Notice of Retraction

The articles, "Influence of Five Different Priming Solutions on Platelet Function in Patients Undergoing Cardiac Surgery,"¹ "Influence of Different Glucose-Insulin-Potassium Regimes on Glucose Homeostasis

29,564 document results

Datos de Scopus hasta hoy

TITLE-ABS-KEY (retracted)

Edit Save Set alert

Search within results...

Refine results

Limit to Exclude

Access type

☐ Open Access (7,787) >

☐ Other (21,777) >

Year

☐ 2021 (10) >

☐ 2020 (1,385) >

☐ 2019 (1,160) >

☐ 2018 (1,256) >

☐ 2017 (1,127) >

☐ 2016 (1,196) >

☐ 2015 (1,447) >

Documents Secondary documents Patents

View Mendeley Data (5135)

Analyze search results

Show all abstracts Sort on: Date (newest)

	Document title	Authors	Year	Source	Cited by
<input type="checkbox"/> 1	Retraction notice to "Mechanical, microstructural and electrical evaluation of reinforced AA5083 with nano-ceramic powders of silicon dioxide SiO ₂ for naval structures" [J. Alloys Compd 842 (2020) 155907] (Journal of Alloys and Compounds (2020) 842, (S0925838820322714), (10.1016/j.jallcom.2020.155907))	Abu-Okail, M., Abdelraouf, Y.A., EL Sayed, E.M., Abu-Oqail, A., Farouk, W.M.	2021	Journal of Alloys and Compounds 853,157044	0

View abstract Enlaces CSIC

<input type="checkbox"/> 2	Retraction notice to "Microstructural variation at interface during fiber laser joining of NiTi/Ti6Al4V and effect of mechanical strength" [PROTEC 282 (2020) 116661][S0924013620300753](10.1016/j.jmatprotec.2020.116661) Open Access	Chatterjee, S., Pandey, A.K., Mahapatra, S.S., Arora, K.S., Behera, A.	2021	Journal of Materials Processing Technology 288,116863	0
----------------------------	--	--	------	---	---

View abstract Enlaces CSIC

☐ 3 Retraction notice to "Effect of sinte

NIH National Library of Medicine National Center for Biotechnology Information

PubMed.gov

retracted publication [pt]

Search

Advanced Create alert Create RSS

User Guide

Save

Email

Send to

Sorted by: Best match

Display options

MY NCBI FILTERS

8,134 results

RESULTS BY YEAR



1959 2020

TEXT AVAILABILITY

☐ Abstract
☐ Free full text
☐ Full text

☐ 1 **RETRACTED: Prevalence of unprofessional social media content among young vascular surgeons.**


Cite Hardouin S, Cheng TW, Mitchell EL, Rauli SJ, Jones DW, Siracuse JJ, Farber A.
J Vasc Surg. 2020 Aug;72(2):667-671. doi: 10.1016/j.jvs.2019.10.069. Epub 2019 Dec 25.
Share PMID: 31882313 **Retracted.**

☐ 2 **A Black Hole at the Center of Earth Plays the Role of the Biggest System of Telecommunication for Connecting DNAs, Dark DNAs and Molecules of Water on 4+N- Dimensional Manifold.**


Cite Fioranelli M, Sepehri A, Rocca MG, Linda C, Rossi C, Vojvodic P, Lotti J, Barygina V, Vojvodic A, Wollina U, Tirant M, Thuong NV, Lotti T.
Share Open Access Maced J Med Sci. 2019 Aug 30;7(18):3073-3080. doi: 10.3889/oamjms.2019.77623
eCollection 2019 Sep 30.
PMID: 31850126 **Free PMC article. Retracted.**

Retractación y citación

10 artículos retractados con mayor no. citas



Grafica a partir de datos de
<https://retractionwatch.com/the-retraction-watch-leaderboard/top-10-most-highly-cited-retracted-papers/>




Ejemplo de artículo publicado
 en 1999 retractado en 2013
 (datos de ScienceDirect)



Bar-Ilan, J., & Halevi, G. (2017). Post retraction
 citations in context: a case study.
Scientometrics, 113(1), 547–565.
<https://doi.org/10.1007/s11192-017-2242-0>

What to do if you suspect fabricated data

(a) Suspected fabricated data in a submitted manuscript



<https://publicationethics.org/guidance/Flowcharts>



Developed for
COPE by Liz Wager
of Sideview
(www.lizwager.com)
© 2013 Committee
on Publication Ethics
First published 2006

A non-exclusive
licence to reproduce
these flowcharts
may be applied
for by writing to:
cope_administrator@
publicationethics.org

Standardised Retraction Form

This retraction template checklist was designed to support editors when preparing a retraction notice, and help researchers analyse retractions.

This template helps editors and journal managers understand whether an article meets the pre-requisites for the COPE retraction guidelines*.

The form consists of tick boxes and space for supporting clarification, to indicate who is retracting the article, the reason for the retraction and history of errata/ expressions of concern. A free text box allows the editor to add any information they consider useful, and a final Retraction Notice box is provided to summarise the details in the form into text to be published to announce the retraction.

Reference of the retracted article:			
DOI:			
Retraction Date:	Day	Month	Year
Retraction requested by (multiple responses allowed):			
<input type="checkbox"/> All Authors			
<input type="checkbox"/> Some of the Authors. Names:			
<input type="checkbox"/> Editor as requested by:			
<input type="checkbox"/> Institution			
<input type="checkbox"/> Reader			
<input type="checkbox"/> Other (details)			

Recommendations



Read the Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals.

Conflicts of Interest



Use the ICMJE Form for Disclosure of Potential Conflicts of Interest to generate a disclosure statement for your manuscript.

Appendix: Ethics



EASE Ethics Checklist for Authors

EXPLANATION: obligatory declarations applying to all manuscripts are printed in bold.

Original or acceptable secondary publication

- ☐ No part of this manuscript (MS) has been published, except for passages that are properly cited.
- ☐ An abstract/summary of this MS has been published in.....
- ☐ This MS has already been published in but in language. A full citation to the primary publication is included, and the copyright owner has agreed to its publication in English.
- ☐ No part of this MS is currently being considered for publication elsewhere.
- ☐ In this MS, original data are clearly distinguished from published data. All information extracted from other publications is provided with citations.

Authorship

- ☐ All people listed as authors of this MS meet the authorship criteria, ie they contributed substantially to study planning, data collection or interpretation of results and wrote or critically revised the MS and approved its final submitted version and agree to be accountable for all aspects of the work (ICMJE 2015).
- ☐ All people listed as authors of this MS are aware of it and have agreed to be listed.
- ☐ No person who meets the authorship criteria has been omitted.

Ethical experimentation and interpretation

- ☐ The study reported in this MS involved human participants and it meets the ethical principles of the Declaration of Helsinki (WMA 2013). Data have been disaggregated by sex (and, whenever possible, by race) and sex and gender considerations are properly addressed (see Sex and Gender Questions²).
- ☐ The study reported in this MS meets the Consensus Author Guidelines on Animal Ethics and Welfare for /eterinary Journals³ about humane treatment of animals and has been approved by an ethical review committee. the study reported in this MS meets other ethical principles, namely

presentation, interpretation, etc. However, if we discover any serious error in the MS (before or after publication), we will alert the editor promptly.

- ☐ None of our data presented in this MS has been fabricated or distorted, and no valid data have been excluded. Images shown in figures have not been manipulated to make a false impression on readers.
- ☐ Results of this study have been interpreted objectively. Any findings that run contrary to our point of view are discussed in the MS.
- ☐ The article does not, to the best of our knowledge, contain anything that is libellous, illegal, infringes anyone's copyright or other rights, or poses a threat to public safety.

Acknowledgements

- ☐ All sources of funding for the study reported in this MS are stated.
- ☐ All people who are not listed as authors but contributed considerably to the study reported in this MS or assisted in its writing (eg author's editors, translators, medical writers) are mentioned in the Acknowledgements.
- ☐ All people named in the Acknowledgements have agreed to this. However, they are not responsible for the final version of this MS.
- ☐ Consent has been obtained from the author(s) of unpublished data cited in the MS.
- ☐ Copyright owners of previously published figures or tables have agreed to their inclusion in this MS.

Conflict of interest

- ☐ All authors of this study have signed the EASE Form for Authors' Contributions and Conflict of Interest Disclosure¹.

Date:.....

Corresponding author:.....

MS title:.....

Compiled by Sylwia Ufnalska
sylwia.ufnalska@gmail.com

¹ <http://www.ease.org.uk/publications/sex-and-gender>
² <https://www.veterinaryjournal.com/consensus-author-guidelines.com>

Council of Science Editors

Publications - Events - About - Resource Library - News - Membership -

Home / Resource Library / Editorial Policies / Retraction Resources

Retraction Resources

PURPOSE

This compilation of primary guidance documents and other materials provides information related to handling retractions of scientific publications. All resources in this collection have been developed by respected authorities and professional groups and are linked here in one location as an aid for editors and others involved in

Upcoming Events

2021 CSE ANNUAL MEETING »

2022 CSE ANNUAL MEETING »

EASE Form for Authors' Contributions and Conflict of Interest Disclosure

European
Association of
Science
Editors

EASE

Journal title:..... Date of submission:

Manuscript title:.....

Corresponding author's name and e-mail:.....

By signing the form, the authors agree to publication of their paper in the journal and certify that the paper is not considered for publication elsewhere. The form is intended for use by scientific journals during or soon after manuscript submission and can be supplemented with the **EASE Ethics Checklist for Authors** (www.ease.org.uk/publications/ease-checklist), to be signed by the corresponding author only. The checklist is part of the practical *EASE Guidelines for Authors and Translators of Scientific Articles*, freely available in >20 languages at www.ease.org.uk/publications/author-guidelines.

First and family names of authors	Contributions to this study and paper								Conflict of interest: financial or personal**	Signature
	(1a) study planning	(1b) data acquisition	(1c) data analysis/ interpretation	(2a) manuscript writing	(2b) manuscript revision	(3) final approval	(4) agreement to be accountable for all aspects of the work*	other* (specify)		
	Yes/No	Yes/No	Yes/No	Yes/No	Yes/No	Yes/No	Yes/No		Yes/No	
	Yes/No	Yes/No	Yes/No	Yes/No	Yes/No	Yes/No	Yes/No		Yes/No	
	Yes/No	Yes/No	Yes/No	Yes/No	Yes/No	Yes/No	Yes/No		Yes/No	
	Yes/No	Yes/No	Yes/No	Yes/No	Yes/No	Yes/No	Yes/No		Yes/No	
	Yes/No	Yes/No	Yes/No	Yes/No	Yes/No	Yes/No	Yes/No		Yes/No	
	Yes/No	Yes/No	Yes/No	Yes/No	Yes/No	Yes/No	Yes/No		Yes/No	
	Yes/No	Yes/No	Yes/No	Yes/No	Yes/No	Yes/No	Yes/No		Yes/No	
	Yes/No	Yes/No	Yes/No	Yes/No	Yes/No	Yes/No	Yes/No		Yes/No	
	Yes/No	Yes/No	Yes/No	Yes/No	Yes/No	Yes/No	Yes/No		Yes/No	

* Each author must ensure that questions related to the accuracy or integrity of any part of the study and manuscript are appropriately investigated and resolved, see ICMJE authorship criteria (<http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html>). **Each person who meets criterion 1 (1a or 1b or 1c) should be allowed to participate in the drafting (criterion 2a or 2b) and approval of the final version of the manuscript (criterion 3). The contributions of people who met only one or two authorship criteria should be mentioned in Acknowledgements, but their names should be given only if the people agree to it.**

** Financial conflicts of interest include (but are not restricted to) employment, consultancies, stock ownership, honoraria, paid expert testimony or speakers' bureau, while non-financial conflicts of interest include personal relationships or competitiveness in academic community. **If in doubt or if a conflict of interest exists, the author should complete also the ICMJE Form for Disclosure of Potential Conflicts of Interest** (www.icmje.org/coi_disclosure.pdf).

Published by the European Association of Science Editors (www.ease.org.uk/publications/ease-form), July 2015



DECLARACIÓN DE HELSINKI DE LA AMM – PRINCIPIOS ÉTICOS PARA LAS INVESTIGACIONES MÉDICAS EN SERES HUMANOS



Adoptada por la
18ª Asamblea Médica Mundial, Helsinki, Finlandia, junio 1964
y enmendada por la
29ª Asamblea Médica Mundial, Tokio, Japón, octubre 1975
35ª Asamblea Médica Mundial, Venecia, Italia, octubre 1983
41ª Asamblea Médica Mundial, Hong Kong, septiembre 1989
48ª Asamblea General Somerset West, Sudáfrica, octubre 1996

21st marzo 2017

Tipos de políticas

Declaración

nombre

<https://www.wma.net/es/policies-post/declaracion-de-helsinki-de-la-amm-principios-eticos-para-las-investigaciones-medicas-en-seres-humanos/>

Reglamento General de Protección de Datos (RGPD) de 28 de mayo de 2018
[Ley Orgánica 3/2018](#), de 5 de diciembre, de Protección de Datos Personales y garantía de los derechos digitales.

LOS DERECHOS QUE TIENES PARA PROTEGER TUS DATOS PERSONALES

EL 25 DE MAYO DE 2018 SE APLICA EL REGLAMENTO EUROPEO DE PROTECCIÓN DE DATOS Y ES IMPORTANTE QUE CONOZCAS CUÁLES SON TUS DERECHOS



<https://www.aepd.es/infografias/index.html>

<http://www.enrio.eu/resources/?cat=6>



Aprende jugando.....



Get peered <https://www.bmj.com/content/327/7429/1439> Dibujo de Malcom Willett <http://www.willett-ink.co.uk/>

Gracias y
¡Feliz aniversario!!!

